DUBLIN–(BUSINESS WIRE)–The “FMS-like tyrosine kinase 3 inhibitors – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “FMS-like tyrosine kinase 3 inhibitors – Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the FMS-like tyrosine kinase 3 inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence FMS-like tyrosine kinase 3 inhibitors R&D. The therapies under development are focused on novel approaches for FMS-like tyrosine kinase 3 inhibitors.
FMS-like tyrosine kinase 3 inhibitors Emerging Drugs Chapters
This segment of the FMS-like tyrosine kinase 3 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
FMS-like tyrosine kinase 3 inhibitors Emerging Drugs
CG-806: Aptose Biosciences
CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor. This small molecule, in-licensed from CrystalGenomics in Seoul, South Korea, demonstrates potent inhibition of wild type and all mutant forms of FLT3 (including internal tandem duplication, or ITD, and mutations of the receptor tyrosine kinase domain and gatekeeper region), cures animals of acute myeloid leukemia (AML) tumors in the absence of toxicity in murine xenograft models. The drug is in Phase I/II clinical studies for the treatment of CLL & NHL.
Quizartinib: Daiichi Sankyo Company
Quizartinib is an orally administered, small molecule FLT3 kinase inhibitor. Quizartinib was approved by the Ministry of Health, Labor and Welfare (MHLW) of Japan under the brand name of VANFLYTA for the treatment of adult patients with relapsed/refractory FLT3-ITD AML on June 18, 2019. Quizartinib is currently being studied alone or in combination with other agents as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in adult and pediatric populations.
Major Players working on FMS-like tyrosine kinase 3 inhibitors
There are approx. 25+ key companies which are developing the FMS-like tyrosine kinase 3 inhibitors. The companies which have their FMS-like tyrosine kinase 3 inhibitors drug candidates in the most advanced stage, i.e. Phase III, include Quizartinib.
Key Players
- Aptose Biosciences
- Daiichi Sankyo Company
- Celon Pharma
- AROG Pharmaceuticals
- Pfizer
- Ascentage Pharma
- Pharos I&BT Co
- Novartis Oncology
- Exelixis
- Ipsen
Key Products
- CG-806
- Quizartinib
Research program: small molecule anti-cancer therapeutics
- Crenolanib
- Olverembatinib
- PHI-101
- Midostaurin
- Cabozantinib
Key Topics Covered:
Introduction
Executive Summary
FMS-like tyrosine kinase 3 inhibitors: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
FMS-like tyrosine kinase 3 inhibitors – Analytical Perspective
In-depth Commercial Assessment
- FMS-like tyrosine kinase 3 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
FMS-like tyrosine kinase 3 inhibitors Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
Quizartinib: Daiichi Sankyo Company
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Coltuximab Ravtansine: Sanofi
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
CG-806: Aptose Biosciences
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
RC58: RemeGen
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
FMS-like tyrosine kinase 3 inhibitors Key Companies
FMS-like tyrosine kinase 3 inhibitors Key Products
FMS-like tyrosine kinase 3 inhibitors – Unmet Needs
FMS-like tyrosine kinase 3 inhibitors – Market Drivers and Barriers
FMS-like tyrosine kinase 3 inhibitors – Future Perspectives and Conclusion
FMS-like tyrosine kinase 3 inhibitors Analyst Views
FMS-like tyrosine kinase 3 inhibitors Key Companies
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7xsiwj
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900